STRS Ohio’s Maze Therapeutics MAZE Stock Holding History

STRS Ohio’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,300	Closed	-$188K	–	2364
2026 Q1	$188K	Sell	6,300 -4,900	-44%	-$216K	﹤0.01%	1520
2025 Q4	$464K	Sell	11,200 -6,700	-37%	-$230K	﹤0.01%	1137
2025 Q3	$464K	Sell	17,900 -29,000	-62%	-$490K	﹤0.01%	1137
2025 Q2	$575K	Buy	46,900 +45,300	+2,831%	+$471K	﹤0.01%	1168
2025 Q1	$17.6K	Buy	+1,600	New	+$19.3K	﹤0.01%	1856

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

STRS Ohio's MAZE Position: Q2 2026 in Review

STRS Ohio sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 6,300 shares — an estimated $188K sold.

STRS Ohio first reported a position in MAZE in Q1 2025 and held it in 5 quarters. The position peaked at $575K in Q2 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

STRS Ohio reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
STRS Ohio sold 6,300 Maze Therapeutics shares in Q2 2026, an estimated $188K.
STRS Ohio first reported a position in Maze Therapeutics in Q1 2025 and held it in 5 quarters.
STRS Ohio's Maze Therapeutics position peaked at $575K in Q2 2025.
162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.